Deflazacort

Deflazacort
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	H02AB13 (WHO) ;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Renal (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
CAS Number	14484-47-0 ;
PubChem CID	26709;
ChemSpider	164861 ;
UNII	KR5YZ6AE4B;
KEGG	D03671 ;
ChEMBL	ChEMBL1201891 ;
CompTox Dashboard (EPA)	DTXSID9020378 ;
ECHA InfoCard	100.034.969
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.517 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
	(what is this?) (verify)

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.^[1] Its potency is around 70–90% that of prednisone.^[2]

It is sold in Bangladesh as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the United Kingdom by Shire under the trade name Calcort;^[2] in Brazil as Cortax, Decortil, and Deflanil; in India as MOAID, ZENFLAV BY TIGRIS, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.^[3] It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. ^[4]

References

^ Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. PMID 7494809.
^ ^a ^b "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.
^ "Substâncias: DEFLAZACORT" (in Portuguese). Centralx. 2008. Retrieved on October 28, 2008.
^ http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

[1] Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. PMID 7494809.

[eMC-2] "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.

[Centralx-3] "Substâncias: DEFLAZACORT" (in Portuguese). Centralx. 2008. Retrieved on October 28, 2008.

[4] ttp://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1

[1]

[2]

[3]

[4]